Weight gain in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 386-393

  Jacob, A N ^a   Salinas, K ^a   Adams Huet, B ^a,b   Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Insulin; Metformin; Pioglitazone; Resting energy expenditure; Type 2 diabetes; Visceral and subcutaneous fat; Weight gain

Indexed keywords

ADIPONECTIN; GHRELIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LEPTIN; METFORMIN; PIOGLITAZONE;

ABDOMINAL PAIN; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BODY FAT; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KNEE INJURY; LEAN BODY WEIGHT; LEG EDEMA; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; WEIGHT; WEIGHT GAIN;

EID: 33947687181     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00622.x     Document Type: Article

References (22)

1. UKPDS Group. UK Prospective Diabetes Study 16: Overview of 6 years' therapy on type II diabetes: A progressive disease. Diabetes 1995; 44: 1249-1258.
2. The DCCT Research Group. Weight gain associated with intensive therapy in the DCCT. Diabetes Care 1988; 11: 567-573.
3. Yki-Jarvinen H, Nikkila K, Makimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58 (Suppl. 1): 53-54; discussion 75-82.
4. Hall SE, Saunders J, Sonksen PH. Glucose and free fatty acid turnover in normal subject and in diabetic subject before and after insulin treatment. Diabetologia 1979; 16: 297-306.
5. Nair KS, Garrow JS, Ford C et al. Effect of poor diabetic control and obesity on whole body protein metabolism in man. Diabetologia 1983; 25: 400-403.
6. Torbay N, Bracco EF, Geliebter A. Insulin increases body fat despite control of feed intake and physical activity. Am J Physiol 1985; 248: R120-R124.
7. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989; 38: 550-557.
8. Schmidt MI, Watson RL, Duncan BB et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 1996; 45: 699-706.
9. Wagenknecht LE, Langefeld CD, Scherzinger AL et al. Insulin sensitivity, insulin secretion, and abdominal fat. Diabetes 2003; 52: 2490-2496.
10. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 1984; 288: 1401-1404.
11. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor-γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
12. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetes patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
13. Takei I, Takayama S, Yamauchi A et al. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: a preliminary report. Eur J Clin Nutr 1998; 52: 153-154.
14. Jackson AS, Pollock ML. Generalized equations for predicting body density of men. Br J Nutr 1978; 40: 497-504.
15. Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body density of women. Med Sci Sports Exerc 1980; 12: 175-182.
16. Ainsworth BE, Haskell WL, Whitt MC et al. Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: S498-S504.
17. Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction of total subcutaneous, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single magnetic resonance imaging slice. Am J Clin Nutr 1997; 65: 403-408.
18. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: A randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
19. Strowig SM, Avilés-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-1698.
20. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ.; the Metformin Trial Groups. Continuing metformin when starting insulin in patients with type 2 diabetes: A double-blind randomized placebo-controlled trial. Diabet Med 2005; 22: 634-640.
21. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992-5995.
22. O'Rahilly S, Farooqi S, Yeo GSH, Challis BG. Minireview: Human obesity - lessons from monogenic disorders. Endocrinology 2003; 144: 3757-3764.